FDA to allow Pfizer-BioNTech vaccine to be stored at higher temps: NYT (Reuters) – The U.S. Food & Drug Administration plans to approve Pfizer Inc and BioNTech SE’s request to store their COVID-19 vaccine at standard freezer temperatures instead of in ultra-cold conditions, the New York Times reported on Tuesday. The FDA is expected to […]
Drugmakers should test any Covid-19 vaccines that have been retooled to combat new variants of the coronavirus in clinical trials designed to track the immune response of hundreds of subjects, which could take months, U.S. regulators said on Feb. 22.
Drug developer Novavax Inc. completed enrolling 30,000 volunteers in a late-stage study of the company’s Covid-19 vaccine in the United States and Mexico.
U.S. President Joe Biden secured a commitment from Pfizer Inc. to double the Covid-19 vaccine the company churns out in the coming weeks, putting his goal to fill the country’s inoculation stockpile by summer in sight.
Novavax announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to provide 1.1 billion doses of the company’s Covid-19 vaccine candidate NVX-CoV2373 for the COVAX Facility.
The two Covid-19 vaccines approved for use in the United States have reassuring safety profiles, the U.S. Centers for Disease Control and Prevention said on Feb. 19 after monitoring the first month of vaccinations between December 2020 and January 2021.
AstraZeneca and Oxford University’s Covid-19 vaccine is more effective when its second dose is given three months after the first, instead of six weeks, a peer-reviewed study published in The Lancet medical journal showed on Feb. 19.
Pfizer Inc. and BioNTech SE asked the U.S. health regulator to relax requirements for their Covid-19 vaccine to be stored at ultra-low temperatures, potentially allowing for it to be kept in pharmacy freezers.
Pfizer’s Covid-19 vaccine greatly reduces virus transmission, according to two Israeli studies, shedding light on one of the biggest questions of the global effort to quash the pandemic.
Pfizer Inc. and BioNTech SE started an international study with 4,000 volunteers to evaluate the safety and effectiveness of their COVID-19 vaccine in healthy pregnant women.